Capital Performance Advisors LLP Purchases New Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Capital Performance Advisors LLP acquired a new stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 4,007 shares of the biopharmaceutical company’s stock, valued at approximately $45,000.

A number of other institutional investors have also recently added to or reduced their stakes in DVAX. AlphaCentric Advisors LLC increased its stake in shares of Dynavax Technologies by 55.0% during the 3rd quarter. AlphaCentric Advisors LLC now owns 201,500 shares of the biopharmaceutical company’s stock worth $2,245,000 after purchasing an additional 71,500 shares during the last quarter. James Investment Research Inc. increased its position in Dynavax Technologies by 14.1% during the third quarter. James Investment Research Inc. now owns 67,134 shares of the biopharmaceutical company’s stock worth $748,000 after buying an additional 8,304 shares during the last quarter. US Bancorp DE raised its holdings in Dynavax Technologies by 291.4% during the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 2,034 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Dynavax Technologies by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 25,204 shares of the biopharmaceutical company’s stock worth $281,000 after acquiring an additional 9,827 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Dynavax Technologies by 44.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 1,679 shares during the last quarter. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Dynavax Technologies Trading Up 8.2 %

Shares of DVAX stock opened at $13.01 on Monday. The firm has a market capitalization of $1.70 billion, a P/E ratio of 118.28 and a beta of 1.34. Dynavax Technologies Co. has a 1 year low of $9.74 and a 1 year high of $15.01. The firm’s fifty day simple moving average is $11.16 and its 200 day simple moving average is $11.24. The company has a current ratio of 14.18, a quick ratio of 13.18 and a debt-to-equity ratio of 0.35.

Analyst Upgrades and Downgrades

DVAX has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and issued a $29.00 target price on shares of Dynavax Technologies in a report on Friday. The Goldman Sachs Group decreased their price target on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a report on Thursday, August 8th.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.